CO2021009882A2 - Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer - Google Patents
Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncerInfo
- Publication number
- CO2021009882A2 CO2021009882A2 CONC2021/0009882A CO2021009882A CO2021009882A2 CO 2021009882 A2 CO2021009882 A2 CO 2021009882A2 CO 2021009882 A CO2021009882 A CO 2021009882A CO 2021009882 A2 CO2021009882 A2 CO 2021009882A2
- Authority
- CO
- Colombia
- Prior art keywords
- mat2a
- methods
- aza
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente descripción proporciona compuestos de acuerdo con la Fórmula I, Fórmula II, y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la isoforma 2A de la metionina adenosiltransferasa (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para tratar cánceres, que incluyen algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785574P | 2018-12-27 | 2018-12-27 | |
PCT/US2019/068653 WO2020139992A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021009882A2 true CO2021009882A2 (es) | 2021-10-29 |
Family
ID=69400626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0009882A CO2021009882A2 (es) | 2018-12-27 | 2021-07-27 | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220098203A1 (es) |
EP (1) | EP3902804A1 (es) |
JP (1) | JP2022516882A (es) |
KR (1) | KR20220050832A (es) |
CN (1) | CN113474347A (es) |
AR (1) | AR115296A1 (es) |
AU (1) | AU2019414446A1 (es) |
BR (1) | BR112021012599A2 (es) |
CA (1) | CA3124678A1 (es) |
CL (1) | CL2021001722A1 (es) |
CO (1) | CO2021009882A2 (es) |
CR (1) | CR20210409A (es) |
EA (1) | EA202191800A1 (es) |
IL (1) | IL284324A (es) |
JO (1) | JOP20210171A1 (es) |
MA (1) | MA54609A (es) |
MX (1) | MX2021007833A (es) |
PE (1) | PE20212303A1 (es) |
SG (1) | SG11202106627WA (es) |
TW (1) | TW202039489A (es) |
WO (1) | WO2020139992A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202105469YA (en) | 2018-12-10 | 2021-06-29 | Ideaya Biosciences Inc | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
PL3902803T3 (pl) * | 2018-12-27 | 2023-05-22 | Les Laboratoires Servier | Aza-heterobicykliczne inhibitory mat2a i sposoby zastosowania do leczenia nowotworu |
CA3177164A1 (en) * | 2020-04-28 | 2021-11-04 | Peter Sennhenn | Bicyclic kinase inhibitors and uses thereof |
CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
WO2022143864A1 (zh) * | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
WO2023066283A1 (en) | 2021-10-20 | 2023-04-27 | Insilico Medicine Ip Limited | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof |
AU2022423231A1 (en) * | 2021-12-21 | 2024-07-11 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Methionine adenosyltransferase 2a heterocyclic inhibitor |
CN118541371A (zh) * | 2022-01-26 | 2024-08-23 | 勤浩医药(苏州)有限公司 | 用于治疗mtap缺失型癌症的甲硫氨酸腺苷转移酶2a抑制剂 |
WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业(成都)有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
KR20240051860A (ko) | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
WO2024183778A1 (zh) * | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
ID28276A (id) * | 1998-10-23 | 2001-05-10 | Hoffmann La Roche | Heterolingkar nitrogen bisiklik |
TR200201057T2 (tr) * | 1999-10-21 | 2002-09-23 | F.Hoffmann-La Roche Ag | P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları. |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
US7084270B2 (en) * | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
US7129351B2 (en) * | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
WO2004089955A1 (en) * | 2003-04-10 | 2004-10-21 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
AU2008266883B2 (en) | 2007-06-20 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
CN104418860B (zh) * | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
EP3507290A1 (en) * | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
CN109384790B (zh) * | 2017-08-08 | 2022-05-10 | 药捷安康(南京)科技股份有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
MA52232A (fr) * | 2018-03-30 | 2021-02-17 | Agios Pharmaceuticals Inc | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
-
2019
- 2019-12-27 EP EP19845797.0A patent/EP3902804A1/en not_active Withdrawn
- 2019-12-27 CA CA3124678A patent/CA3124678A1/en active Pending
- 2019-12-27 BR BR112021012599-0A patent/BR112021012599A2/pt not_active Application Discontinuation
- 2019-12-27 CN CN201980092839.3A patent/CN113474347A/zh active Pending
- 2019-12-27 CR CR20210409A patent/CR20210409A/es unknown
- 2019-12-27 JO JOP/2021/0171A patent/JOP20210171A1/ar unknown
- 2019-12-27 US US17/418,406 patent/US20220098203A1/en active Pending
- 2019-12-27 JP JP2021538125A patent/JP2022516882A/ja active Pending
- 2019-12-27 TW TW108148080A patent/TW202039489A/zh unknown
- 2019-12-27 AU AU2019414446A patent/AU2019414446A1/en not_active Abandoned
- 2019-12-27 AR ARP190103901A patent/AR115296A1/es unknown
- 2019-12-27 WO PCT/US2019/068653 patent/WO2020139992A1/en unknown
- 2019-12-27 PE PE2021001090A patent/PE20212303A1/es unknown
- 2019-12-27 EA EA202191800A patent/EA202191800A1/ru unknown
- 2019-12-27 MX MX2021007833A patent/MX2021007833A/es unknown
- 2019-12-27 SG SG11202106627WA patent/SG11202106627WA/en unknown
- 2019-12-27 KR KR1020217023830A patent/KR20220050832A/ko unknown
- 2019-12-27 MA MA054609A patent/MA54609A/fr unknown
-
2021
- 2021-06-23 IL IL284324A patent/IL284324A/en unknown
- 2021-06-25 CL CL2021001722A patent/CL2021001722A1/es unknown
- 2021-07-27 CO CONC2021/0009882A patent/CO2021009882A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220050832A (ko) | 2022-04-25 |
PE20212303A1 (es) | 2021-12-10 |
EP3902804A1 (en) | 2021-11-03 |
MA54609A (fr) | 2022-04-06 |
MX2021007833A (es) | 2021-10-26 |
US20220098203A1 (en) | 2022-03-31 |
CL2021001722A1 (es) | 2022-02-18 |
AR115296A1 (es) | 2020-12-16 |
SG11202106627WA (en) | 2021-07-29 |
EA202191800A1 (ru) | 2021-09-13 |
AU2019414446A1 (en) | 2021-07-15 |
CR20210409A (es) | 2022-01-24 |
JP2022516882A (ja) | 2022-03-03 |
JOP20210171A1 (ar) | 2023-01-30 |
IL284324A (en) | 2021-08-31 |
CA3124678A1 (en) | 2020-07-02 |
WO2020139992A1 (en) | 2020-07-02 |
TW202039489A (zh) | 2020-11-01 |
CN113474347A (zh) | 2021-10-01 |
BR112021012599A2 (pt) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
CO2021017981A2 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer | |
CO2021009879A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
CO2021008895A2 (es) | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a | |
EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
MX2022002219A (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
UY39477A (es) | Compuestos espiro heterocíclicos y métodos de uso | |
ECSP21026485A (es) | Piridazinonas y sus métodos de uso | |
ECSP22043592A (es) | Inhibidores de egfr alost?ricos y m?todos de uso de los mismos | |
CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer | |
CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
EA202092016A1 (ru) | Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b | |
AR114282A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”) |